OUTCOMES OF CORNEAL ALLERGENIC INTRASTROMAL RING SEGMENT (CAIRS) SURGERY
Dr David Gunn, Ophthalmologist
Cornea, Cataract and Refractive Surgeon, Queensland Eye Institute
& Focus Vision Clinic in Brisbane, Queensland
RESEARCHER PROFILE (Filmed in Brisbane, Queensland, Australian | June 2024)
Dr David Gunn is an ophthalmologist specialising in cornea, cataract, and refractive surgery at the Queensland Eye Institute and Focus Vision in Brisbane, Queensland. His journey into ophthalmology began during medical school, inspired by a mentor. He initially engaged in research on mouse glaucoma, exploring amacrine cells and their responses.
After completing his residency and gaining experience in eye casualty at the Royal Brisbane Hospital, David underwent four years of surgical training in the Queensland network. This was followed by a stint at the Bristol Eye Hospital in the UK, focusing on the cornea and anterior segment. Since returning to Queensland, he has concentrated on keratoconus research.
One of the pivotal moments in his career was the decision to specialise in cornea surgery, which included performing Australia’s first CAIRS procedure in May 2021. His current research examines outcomes for patients undergoing Corneal Allergenic Intrastromal Ring Segment (CAIRS) surgery.
Dr Gunn finds immense satisfaction in the immediate post-operative results he sees in patients, as visual acuity provides a tangible measure of success. He is passionate about introducing less invasive surgical techniques that lead to improvements in patients’ lives.
You Might also like
-
De-prescribing medications in older adults with dementia
Dr. Daniel Hoyle is a Senior Lecturer in Therapeutics and Pharmacy Practice at the School of Pharmacy and Pharmacology, University of Tasmania. He is also an experienced clinical pharmacist with expertise in medication management in older people. Dr. Hoyle’s research interests focus on improving medicine use in older people with dementia.
-
Investigating the benefits of donor human milk for preterm infants
Together, SAHMRI and Lifeblood are leading a consortium to revolutionise the way human milk, and novel products made from human milk, are used as nutritional and medical interventions to improve health outcomes in vulnerable infants, but with potential application for a diverse range of medical indications.
Currently, babies who are born early preterm – before 32 weeks – are given donor milk when their own mother’s milk is not available or in short supply. Whether donor milk is beneficial for babies born just a few weeks early is unclear, as very little research has been undertaken with these babies.
The GIFT Trial will soon commence as an investigation between SAHMRI, the University of Adelaide, the Red Cross Lifeblood Milk Bank conducted at five sites across three states in Australia.
-
RESEARCH IMPACT SAHMRI, SOUTH AUSTRALIA (2023)
South Australian Health and Medical Research Institute, also known as SAHMRI has had significant impacts in various areas over the past ten years, and this year is celebrating its 10 year anniversary with a week of events.
Ahead of the anniversary, Executive Director, Professor Maria Makrides spoke to Bench Side Story about 3 achievements in the past 10 years that have had significant impact